Reshaping Novartis into a more aggressive pharma giant, Vas Narasimhan bags a $13B consumer sale ahead of bolt-on deals
Vas Narasimhan has begun to reshape the giant Novartis into the drugs and data sciences behemoth he has in mind, striking a deal to sell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
